The Musashi-2 expression signature can be used as a novel indicator for predicting the clinical outcomes of ccRCC patients and will help us to deeply explore the roles of cellular metabolic reprogramming and immune infiltration in ccRCC. This evidence concerns the gene MSI2 and nonpapillary renal cell carcinoma.